Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.47 |
| ▸ | NPC1 | O15118 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | G6PD | P11413 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4279223 | 0.88 | L3MBTL1 (0.44) | L3MBTL1SMN1; SMN2NPC1MAPTMEN1 | |
| SCHEMBL22000046 | 0.81 | TDP1 (0.51) | L3MBTL1MAPTMEN1KMT2ATDP1 | |
| SCHEMBL412611 | 0.80 | MRGPRX4 (0.44) | L3MBTL1MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL8161648 | 0.80 | ALDH1A1 (0.44) | L3MBTL1SMN1; SMN2NPC1MAPTMEN1 | |
| SCHEMBL263774 | 0.80 | PKM (0.56) | L3MBTL1SMN1; SMN2NPC1MAPTMEN1 | |
| SCHEMBL8156344 | 0.80 | KDM4E (0.56) | L3MBTL1SMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL18783666 | 0.79 | MAPT (0.41) | L3MBTL1MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL16651556 | 0.79 | ALDH1A1 (0.41) | L3MBTL1SMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL7832979 | 0.79 | MAPT (0.61) | L3MBTL1SMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL12017816 | 0.79 | CYP1A2 (0.53) | L3MBTL1SMN1; SMN2NPC1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-12509474-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20240109920-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2024-04-04 | — | — | US | disclosed |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| CN-116947903-A | Inhibitors of complement factors and uses thereof | 安尼艾克松股份有限公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-116261564-A | Inhibitors of complement factors and uses thereof | 安尼艾克松股份有限公司 | 2023-06-13 | — | — | CN | disclosed |
| EP-4185592-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | Annexon, Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2022-02-17 | — | — | US | disclosed |
| US-7419984-B2 | Pyrimidines and uses thereof | CELL THERAPEUTICS, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-6855829-B2 | 3-fluoro-2-oxindole modulators of KCNQ potassium channels and use thereof in treating migraine and mechanistically related disease | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-02-15 | — | — | US | disclosed |
| US-20040204386-A1 | Pyrimidines and uses thereof | CELL THERAPEUTICS, INC. | 2004-10-14 | — | — | US | disclosed |
| EP-1441722-A2 | MODULATORS OF KCNQ POTASSIUM CHANNELS AND USE THEREOF IN TREATING MIGRAINE AND MECHANISTICALLY RELATED DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-08-04 | — | — | EP | disclosed |
| EP-1363624-A2 | FLUORO OXINDOLE DERIVATIVES AS MODULATORS OF KCNQ POTASSIUM CHANNELS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-11-26 | — | — | EP | disclosed |
| US-20020156120-A1 | Fluoro oxindole derivatives as modulators of KCNQ potassium channels | BRISTOL-MYERS SQUIBB COMPANY | 2002-10-24 | — | — | US | disclosed |
| US-6469042-B1 | ANALGESICS FOR MIGRAINES | BRISTOL-MYERS SQUIBB COMPANY | 2002-10-22 | — | — | US | disclosed |
| WO-2002072088-A2 | MODULATORS OF KCNQ POTASSIUM CHANNELS AND USE THEREOF IN TREATING MIGRAINE AND MECHANISTICALLY RELATED DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-09-19 | — | — | WO | disclosed |
| US-20020128277-A1 | Modulators of KCNQ potassium channels and use thereof in treating migraine and mechanistically related diseases | BRISTOL-MYERS SQUIBB COMPANY | 2002-09-12 | — | — | US | disclosed |
| WO-2002066426-A2 | FLUORO OXINDOLE DERIVATIVES AS MODULATORS OF KCNQ POTASSIUM CHANNELS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109920-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | L3MBTL1 4785/4885SMN1; SMN2 782/4885NPC1 460/4885 |
| US-20040204386-A1 | Pyrimidines and uses thereof | LPCAT3, LPCAT1, APRT | L3MBTL1 459/4885SMN1; SMN2 4131/4885NPC1 1406/4885 |
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | L3MBTL1 4785/4885SMN1; SMN2 782/4885NPC1 460/4885 |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | CFB, CFH, C9 | L3MBTL1 4785/4885SMN1; SMN2 782/4885NPC1 460/4885 |
| US-20020128277-A1 | Modulators of KCNQ potassium channels and use thereof in treating migraine and mechanistically related diseases | KCNQ5, KCNQ2, KCNQ1 | L3MBTL1 4048/4885SMN1; SMN2 3758/4885NPC1 1175/4885 |
| US-12509474-B2 | Inhibitors of complement factors and uses thereof | SSB, UACA, CFH | L3MBTL1 2967/4885SMN1; SMN2 237/4885NPC1 4343/4885 |
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFH, CFB, C5 | L3MBTL1 3721/4885SMN1; SMN2 1451/4885NPC1 1839/4885 |
| US-20020156120-A1 | Fluoro oxindole derivatives as modulators of KCNQ potassium channels | KCNQ1, KCNQ2, KCNQ3 | L3MBTL1 1319/4885SMN1; SMN2 4092/4885NPC1 1950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.